Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB2 | P30411 | 18/20 | 0.74 |
| ▸ | PREP | P48147 | 1/20 | 0.67 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bradykinin SCHEMBL3047797 | 0.95 | BDKRB2 (0.82) | BDKRB2PREPMRGPRX2 | |
| SCHEMBL29406138 | 0.94 | BDKRB2 (0.80) | BDKRB2PREP | |
| Bradykinin SCHEMBL29530927 | 0.93 | BDKRB2 (0.79) | BDKRB2PREPMRGPRX2 | |
| SCHEMBL29484957 | 0.93 | BDKRB2 (0.79) | BDKRB2PREPMRGPRX2 | |
| SCHEMBL29404860 | 0.93 | BDKRB2 (0.79) | BDKRB2PREPMRGPRX2 | |
| SCHEMBL30526211 | 0.91 | BDKRB2 (0.61) | BDKRB2PREPMRGPRX2 | |
| SCHEMBL29439057 | 0.90 | BDKRB2 (0.69) | BDKRB2 | |
| SCHEMBL29929851 | 0.89 | BDKRB2 (0.74) | BDKRB2 | |
| SCHEMBL29497762 | 0.89 | BDKRB2 (0.77) | BDKRB2PREP | |
| SCHEMBL150645 | 0.89 | BDKRB2 (0.83) | BDKRB2PREPMRGPRX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2025-06-05 | — | — | US | disclosed |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | TUFTS MEDICAL CENTER (US) | 2024-08-13 | — | — | US | disclosed |
| US-20240257973-A1 | DISEASE SPECTRUM CLASSIFICATION | PATIENTSLIKEME LLC (US) | 2024-08-01 | — | — | US | disclosed |
| US-11894139-B1 | Disease spectrum classification | PATIENTSLIKEME LLC (US) | 2024-02-06 | — | — | US | disclosed |
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | BDKRB2 440/4885PREP 3527/4885MRGPRX2 390/4885 |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | BDKRB2 440/4885PREP 3527/4885MRGPRX2 390/4885 |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | LIPG, CD40, LDLR | BDKRB2 415/4885PREP 3387/4885MRGPRX2 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.